Get started
Author

Adekemi B. Taylor

Observed name: Adekemi Taylor
ORCID: 0000-0002-7373-5660
Observed ORCID: 0000-0002-7373-5660
OpenAlex ID: A5111663254
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
2011 · Timothy A. Yap, Li Yan, et al. · Journal of Clinical Oncology · 539
Short-Acting T-Type Calcium Channel Antagonists Significantly Modify Sleep Architecture in Rodents
2010 · Zhi-Qiang Yang, Kelly-Ann S. Schlegel, et al. · ACS Medicinal Chemistry Letters · 20
Three-Dimensional Simulations of Reactive Gas Uptake in Single Airway Bifurcations
2006 · Adekemi B. Taylor, Ali Borhan, et al. · Annals of Biomedical Engineering · 20
Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia
2021 · Adekemi Taylor, Dana Lee, et al. · Clinical Pharmacology in Drug Development · 12
PDF
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
2024 · Bradley J. Monk, Ignacio Romero, et al. · Clinical Therapeutics · 10
PDF
Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer
2025 · Xiaofei Zhou, Xiaoyan Yang, et al. · The Journal of Clinical Pharmacology · 9
PDF
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
2025 · Theodoros Papathanasiou, Josh Kaullen, et al. · Clinical Pharmacokinetics · 8
PDF
Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3
2023 · Geraldine Ferron-Brady, Adekemi Taylor, et al. · Blood · 7
Abstract #3604: A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers
2009 · Michele Trucksis, Evan Friedman, et al. · Cancer Research · 5
Evaluation of pharmacokinetics of intravenous protein C concentrate in protein C deficiency: implications for treatment initiation and maintenance
2025 · Zhaoyang Li, Inmaculada C. Sorribes, et al. · Research and Practice in Thrombosis and Haemostasis · 4
PDF
Changes in the carbon dioxide expirogram in response to ozone exposure
2005 · Adekemi B. Taylor, Genea M. Lee, et al. · Toxicology and Applied Pharmacology · 4
Abstract CT123: Population pharmacokinetics of ripretinib in patients with advanced malignancies
2021 · Suzanne George, Filip Janku, et al. · Cancer Research · 3
Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade
2010 · Timothy A. Yap, Kyriakos Papadopoulos, et al. · Cancer Research · 3
Uptake of Ozone in Human Lungs and Its Relationship to Local Physiological Response
2005 · Wade H. Reeser, Genea M. Lee, et al. · Inhalation Toxicology · 3
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer
2025 · Xiaofei Zhou, Alice Toms, et al. · The Journal of Clinical Pharmacology · 2
PDF
Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer
2024 · Daping Zhang, Adekemi Taylor, et al. · Clinical Pharmacokinetics · 2
PDF
Pharmacokinetic Evidence Supporting Subcutaneous Use of Protein C Concentrate in Patients with Protein C Deficiency
2025 · Zhaoyang Li, Inmaculada C. Sorribes, et al. · TH Open · 1
PDF
Concentration-QTc (C-QTc) Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia
2019 · Adekemi Taylor, Martine Allard, et al. · Blood · 1
Abstract B135: First-in-man, first-in-class phase I study of two schedules of MK-2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC)
2009 · Timothy A. Yap, Kyriakos Papadopoulos, et al. · Molecular Cancer Therapeutics · 1
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA , and Serum M‐Protein in Relapsed/Refractory Multiple Myeloma
2026 · John D. Clements, Inmaculada C. Sorribes, et al. · CPT Pharmacometrics & Systems Pharmacology
PB1140 Pharmacokinetics of intravenous plasma-derived protein C concentrate in pediatric patients with severe protein C deficiency: insights to advance personalized treatment
2026 · Zhaoyang Li, Yvonne Niyonzima, et al. · Research and Practice in Thrombosis and Haemostasis
Simulation Framework to Investigate Efficacy and Ocular Safety of Belantamab Mafodotin Combinations in Relapsed/Refractory Multiple Myeloma
2026 · Fernando Carreño, Martijn van Noort, et al. · CPT Pharmacometrics & Systems Pharmacology
Results from the Summit pivotal trial: Symptom improvement correlates with reductions in objective measures of disease in adults with non-advanced systemic mastocytosis
2026 · Tracy George, Lindsay Rein, et al. · Journal of Allergy and Clinical Immunology
Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites
2025 · Christine Neumar, Liaoliao Li, et al.
Correction: Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer
2024 · Daping Zhang, Adekemi Taylor, et al. · Clinical Pharmacokinetics
PDF
Works count: 27
Citation count: 654
H-index: 7
I10-index: 5
Year
Topic
Type